Evolus reported $90.3 million in Q4 revenue, up 14% year-over-year, and $297.2 million for full-year 2025, up 12%. The company guided 2026 revenue of $327 million to $337 million (10%–13% growth) and expects sustainable profitability with low- to mid-single-digit adjusted EBITDA margins.

Flagship neurotoxin Jeuveau captured over 14% of the U.S. market in 2025, while new filler Evolysse has been purchased by more than 3,000 customers, with mid-face Sculpt approval expected in Q4 2026. Clinical data for Sculpt demonstrated non-inferiority and superiority at primary endpoints, with higher responder rates over two years.

The company trained over 14,000 clinicians in 2025 and launched a portfolio growth rebate in January to reward practices for expanded product purchases. Evolus Rewards, an SMS-based loyalty program, has grown to more than 1.4 million treated patients and offers co-branded media investments tied to purchase volumes.

International revenue nearly doubled to 8% of global sales, driven by a direct model in Germany and partner entry in France, with the U.K. approaching double-digit toxin share. Despite a mid- to upper-single-digit decline in U.S. neurotoxin procedural volumes in 2025, management believes the market stabilized in Q4 and forecasts low single-digit toxin growth for 2026.